We sought to identify previously unknown class 2 CRISPR-Cas systems in terabase-scale metagenomic datasets from groundwater, sediment, acid mine drainage biofilms, soil, infant gut, and other microbial communities. Our analyses targeted large uncharacterized genes proximal to a CRISPR array and *cas1*, the universal CRISPR integrase^[@R8]--[@R10]^. Among the 155 million protein-coding genes analyzed, we identified the first Cas9 proteins in domain Archaea, and discovered in uncultivated bacteria two new CRISPR-Cas systems, which we refer to as CRISPR-CasX and CRISPR-CasY ([Fig. 1](#F9){ref-type="fig"}). Both the archaeal Cas9 and CasY are encoded exclusively in the genomes of organisms from lineages with no known isolated representatives.

One of the hallmarks of CRISPR-Cas9 (type II) systems was their presumed presence only in the bacterial domain^[@R3],[@R11]^. We were therefore surprised to discover Cas9 proteins encoded in genomes of the nanoarchaea ARMAN-1 (*Candidatus* Micrarchaeum acidiphilum ARMAN-1) and ARMAN-4 (*Candidatus* Parvarchaeum acidiphilum ARMAN-4)^[@R12],[@R13]^ in acid-mine drainage (AMD) metagenomic datasets ([Extended Data Table 1](#T1){ref-type="table"} and [Extended Data Fig. 1](#F1){ref-type="fig"}). These findings expand the occurrence of Cas9-containing CRISPR systems to another domain of life.

The CRISPR-Cas locus in ARMAN-1 includes large CRISPR arrays adjacent to *cas1*, *cas2*, *cas4* and *cas9* genes. This system was found on highly similar contigs (average nucleotide identity of 99.7% outside of the CRISPR array) reconstructed independently from 16 different samples. We reconstructed numerous alternative ARMAN-1 CRISPR arrays with a largely conserved end (likely comprised of the oldest spacers) and a variable region into which many distinct spacers have been incorporated ([Fig. 2a](#F10){ref-type="fig"}, [Extended Data Fig. 2](#F2){ref-type="fig"}, and Supplementary Table 1). Given the polarity of the array, we predict that the \~200 bp region between the end of the Cas9 gene and the variable end of the array likely contains the leader sequence and transcriptional start site. Based on the hypervariability in spacer content, we conclude that the ARMAN-1 CRISPR-Cas9 system is active in the sampled populations. Phylogenetic analysis of Cas1 ([Extended Data Fig. 3a](#F3){ref-type="fig"}) suggests that this archaeal CRISPR-Cas system does not clearly fall into any existing type II subtype. The presence of *cas4*, affiliate it with type II-B systems^[@R3],[@R11]^, yet the Cas9 sequence is more similar to type II-C proteins ([Extended Data Fig. 4](#F4){ref-type="fig"}, Supplementary Data 3). Thus, the archaeal type II system may have arisen as a fusion of type II-C and II-B systems ([Extended Data Fig. 3b](#F3){ref-type="fig"}).

Fifty-six of the spacers of the ARMAN-1 CRISPR-Cas9 system target a 10 kbp circular sequence that encodes mostly short hypothetical proteins, and is likely an ARMAN-1 virus ([Fig. 2b](#F10){ref-type="fig"}). Indeed, cryo-electron tomographic reconstructions often identified viral particles attached to ARMAN cells^[@R12],[@R14]^. ARMAN-1 protospacers also derived from a putative transposon within the genome of ARMAN-2 (another nanoarchaeon^[@R13]^) and a putative mobile element in the genomes of *Thermoplasmatales* archaea, including that of I-plasma^[@R15]^ from the same ecosystem ([Extended Data Fig. 5](#F5){ref-type="fig"}). Direct cytoplasmic "bridges" were observed between ARMAN and *Thermoplasmatales* cells, implying a close relationship between them^[@R12],[@R14]^. The ARMAN-1 CRISPR-Cas9 may thus defend against transposon propagation between these organisms, a role that is reminiscent of piRNA-mediated defense against transposition in the eukaryotic germ line^[@R16]^.

Unlike the ARMAN-1 CRISPR-Cas system, the ARMAN-4 *cas9* gene has only one adjacent CRISPR repeat-spacer unit and no other *cas* genes in its vicinity ([Extended Data Fig. 6](#F6){ref-type="fig"}). The lack of a typical CRISPR array and *cas1* points to a system with no capacity to acquire additional spacers. No target could be identified for the spacer sequence, but given the conservation of the locus in samples collected over several years, we cannot rule out it is functional as a "single-target" CRISPR-Cas system. Conservation of a single spacer may indicate that the ARMAN-4 Cas9 exerts an alternative role, such as gene regulation^[@R17]^ or involvement in cell-cell interactions^[@R18]^.

Active DNA-targeting CRISPR-Cas systems use 2 to 4 nt protospacer-adjacent motifs (PAMs) located next to target sequences for self versus non-self discrimination^[@R19],[@R20]^. Examining sequences adjacent to the genomic target sequences revealed a strong 'NGG' PAM preference in ARMAN-1 ([Fig. 2c](#F10){ref-type="fig"}). Cas9 also employs two separate transcripts, CRISPR RNA (crRNA) and trans-activating CRISPR RNA (tracrRNA), for RNA-guided DNA cleavage^[@R21]^. We identified a putative tracrRNA in the vicinity of both ARMAN-1 and ARMAN-4 CRISPR-Cas9 systems ([Extended Data Fig. 7](#F7){ref-type="fig"}). Previously, it was suggested that type II CRISPR systems were absent in archaea due to a lack of the host factor, RNase III, responsible for crRNA-tracrRNA guide complex maturation^[@R11],[@R22]^. Notably, no RNase III homologs were identified in the ARMAN-1 genome (estimated to be 95% complete) and no internal promoters are predicted for the CRISPR array^[@R23]^, suggesting an as-yet undetermined mechanism of guide RNA production. Biochemical experiments to test cleavage activity of ARMAN-1 and ARMAN-4 Cas9 proteins purified from both *E. coli* and yeast and *in vivo E. coli* targeting assays did not reveal any detectable activity (see [Extended Data Table 2](#T2){ref-type="table"} and [Extended Data Fig. 7](#F7){ref-type="fig"}). Given the unique physiology and ecological niche of these nanoarchaea, lack of activity may be due to a post-translational modification or a co-factor absent in the experimental expression systems.

In addition to Cas9, only three families of class 2 Cas effector proteins have been discovered and experimentally validated: Cpf1, C2c1, and C2c2^[@R4],[@R24],[@R25]^. Another gene, *c2c3*, which was identified only on small DNA fragments, has been suggested to also encode such a protein^[@R4]^. We hypothesized that other distinct types of effector proteins might exist within uncultivated microbes whose genomes were reconstructed from our metagenomic datasets. Indeed, a new type of class 2 CRISPR-Cas system was found in the genomes of two bacteria recovered from groundwater and sediment samples^[@R26]^. This system includes Cas1, Cas2, Cas4 and an uncharacterized \~980 aa protein that we refer to as CasX. The high conservation (68% protein sequence identity, Supplementary Data 1) of this protein in two organisms belonging to different phyla, Deltaproteobacteria and Planctomycetes, suggests a recent cross-phyla transfer^[@R29]^. The CRISPR arrays associated with each CasX had highly similar repeats (86% identity) of 37 nt, spacers of 33--34 nt, and a putative tracrRNA between the Cas operon and the CRISPR array ([Fig. 1b](#F9){ref-type="fig"}, [Extended Data Table 1](#T1){ref-type="table"}). BLAST searches revealed only weak similarity (e-value \> 1×10^−4^) to transposases, with similarity restricted to specific regions of the CasX C-terminus. Distant homology detection and protein modeling identified a RuvC domain near the CasX C-terminal end, with organization reminiscent of that found in type V CRISPR-Cas systems ([Extended Data Fig. 3c](#F3){ref-type="fig"}). The rest of the CasX protein (630 N-terminal amino acids) showed no detectable similarity to any known protein, suggesting this is a novel class 2 effector. The combination of tracrRNA and separate Cas1, Cas2 and Cas4 proteins is unique among type V systems, and phylogenetic analyses indicate that the Cas1 from the CRISPR-CasX system is distant from those of any other known type V ([Extended Data Fig. 3a](#F3){ref-type="fig"}). Further, CasX is considerably smaller than any known type V proteins: 980 aa compared to a typical size of \~1,200 aa for Cpf1, C2c1 and C2c3.

To test whether CasX would be capable of RNA-guided DNA targeting analogous to Cas9 and Cpf1 proteins, we synthesized a plasmid encoding a minimal CRISPR-CasX locus including *casX*, a short repeat-spacer array and intervening noncoding regions. We found that when expressed in *E. coli*, this minimal locus blocked transformation by a plasmid bearing a target sequence identified by metagenomic analysis ([Fig. 3a--c](#F11){ref-type="fig"}, [Extended Data Fig. 8](#F8){ref-type="fig"}). Furthermore, interference with transformation occurred only when the spacer sequence in the mini-locus matched the protospacer sequence in the plasmid target.

To identify a PAM sequence for CasX, we repeated the transformation assay in *E. coli* using a plasmid containing either a 5′ or 3′ randomized sequence adjacent to the target site. This analysis revealed a stringent preference for the sequence 'TTCN' located 5′ of the protospacer sequence ([Fig. 3d](#F11){ref-type="fig"}). No 3′ PAM preference was observed ([Extended Data Fig. 8](#F8){ref-type="fig"}). Consistent with this finding, we observed that 'TTCA' is the sequence found upstream of the putative Deltaproteobacteria CRISPR-CasX protospacer that was identified in the environmental samples. Notably, both CRISPR-CasX loci share the same PAM sequence, in line with their high degree of protein sequence homology.

Examples of both single-RNA and dual-RNA guided systems exist among type V CRISPR loci. We used environmental RNA (metatranscriptomic) data to determine whether CasX requires a tracrRNA for DNA targeting activity. This analysis revealed a non-coding RNA transcript with sequence complementarity to the CRISPR repeat encoded between the Cas2 open reading frame and the CRISPR array ([Fig. 3e](#F11){ref-type="fig"}). To check for expression of this non-coding RNA in *E. coli* expressing the CasX locus, Northern blots were conducted against this transcript in both directions ([Extended Data Fig. 8](#F8){ref-type="fig"}). The results showed expression of a transcript of \~110 nt encoded on the same strand as the *casX* gene, with a more heterogeneous transcript of \~60--70 nt, suggesting that the leader sequence for the CRISPR array lies between the tracrRNA and the array. Transcriptomic mapping further suggests that the CRISPR RNA (crRNA) is processed to include \~23 nt of the repeat and 20 nt of the adjacent spacer, similar to the crRNA processing that occurs in CRISPR-Cas9 systems^[@R21],[@R22]^ ([Fig. 3f](#F11){ref-type="fig"}). To determine the dependence of CasX activity on the putative tracrRNA, we deleted this region from the minimal CRISPR-CasX locus described above, and repeated the plasmid interference assays. Deletion of the putative tracrRNA-encoding sequence from the CasX plasmid abolished robust transformation interference ([Fig. 3g](#F11){ref-type="fig"}). This putative tracrRNA was joined with the processed crRNA using a tetraloop to form a single-guide RNA (sgRNA)^[@R21]^. While expression using a heterologous promoter of the crRNA alone or a shortened version of the sgRNA did not have any significant plasmid interference, expression of the full-length sgRNA conferred resistance to plasmid transformation ([Fig. 3g](#F11){ref-type="fig"}). Together, these results establish CasX as a functional DNA-targeting, dual-RNA guided CRISPR-associated protein.

We identified another new class 2 Cas protein encoded in the genomes of certain candidate phyla radiation (CPR) bacteria^[@R6],[@R29]^ ([Fig. 1](#F9){ref-type="fig"}, [Extended Data Table 1](#T1){ref-type="table"}). These bacteria typically have small cell sizes, very small genomes and a limited biosynthetic capacity^[@R6],[@R30]--[@R32]^, indicating they are most likely symbionts^[@R6],[@R30]--[@R33]^. The \~1,200 aa Cas protein, which we named CasY, appears to be part of a minimal CRISPR-Cas system that includes Cas1 and a CRISPR array ([Fig. 4a](#F12){ref-type="fig"}). Most of the CRISPR arrays have unusually short spacers of 17--19 nt, but one system, which lacks Cas1 (CasY.5), has longer spacers (27--29 nt). No predicted tracrRNA was detected in the vicinity of CRISPR-CasY, based on partial complementarity to the repeat sequences; however, we had insufficient metatranscriptomic data mapped to the CasY loci to detect potential tracrRNA sequences. Thus, we cannot exclude the dependence of CasY on a tracrRNA for robust interference from the available data.

The six examples of CasY proteins we identified had no significant sequence similarity to any protein in public databases. A sensitive search using profile Hidden Markov Models (HMMs)^[@R34]^ built from published Cas proteins^[@R3],[@R4]^ indicated that four of the six CasY proteins had local similarities (e-values 4×10^−11^-- 3×10^−18^) to C2c3 in the C-terminal region overlapping the RuvC domains and a small region (\~45 aa) of the N-terminal region (see [Extended Data Fig. 3c](#F3){ref-type="fig"}). The remaining two CasY proteins had no significant similarity to C2c3s, despite sharing significant sequence similarity (best Blast hits: e-values 6×10^−85^, 7×10^−75^) with the other CasY proteins (Supplementary Data 2). C2c3 proteins are putative type V Cas effectors^[@R4]^ that were identified on short contigs with no taxonomic affiliation, and have not been validated experimentally. Strikingly, both CRISPR-CasY and C2c3 were found next to arrays with short spacers and within loci lacking Cas2, a protein considered essential for integrating DNA into the CRISPR array^[@R9],[@R35]^. It remains to be seen whether these type V systems are functional for spacer acquisition.

Given the low homology of CRISPR-CasY to any experimentally validated CRISPR loci, we wondered whether this system confers RNA-guided DNA interference, but due to the short spacer length we did not have reliable information about a possible PAM motif that might be required for such activity. To work around this, the entire CRISPR-CasY.1 locus was synthesized with a shortened CRISPR array and introduced into *E. coli* on a plasmid vector. These cells were then challenged in a transformation assay using a target plasmid with a sequence matching a spacer in the array and containing an adjacent randomized 5′ or 3′ region to identify a possible PAM. Analysis of transformants revealed depletion of sequences containing a 5′ TA directly adjacent to the targeted sequence ([Fig. 4b](#F12){ref-type="fig"}). Based on the identified PAM sequence, the CasY.1 locus was overexpressed using a heterologous promoter and tested against plasmids containing single PAMs. Plasmid interference was strongest in the presence of a target containing the identified 5′ TA PAM sequence ([Fig. 4c](#F12){ref-type="fig"}). Thus, we conclude that CRISPR-CasY has DNA interference activity.

The systems described here are some of the most compact CRISPR-Cas loci identified to date and are found exclusively in metagenomic datasets. The small number of proteins that are required for interference and their relatively short length make these systems especially valuable for the development of genome editing tools. Interestingly, some of these compact loci were identified in organisms with very small genomes. As a consequence of their small genome size, these organisms likely depend on other community members for basic metabolic requirements and thus have remained largely outside the scope of traditional cultivation-based methods. For CasX and CasY, genomic context was critical for predicting functions that would not have been evident from unassembled sequence information. Furthermore, the identification of a putative tracrRNA, as well as targeted sequences uncovered through analysis of the genome-resolved metagenomic data, guided functional testing. Importantly, we show that metagenomic discoveries related to CRISPR-Cas systems are not restricted to *in silico* observations, but can be introduced into an experimental setting where their activity can be analyzed. Given that virtually all environments where life exists can now be probed by metagenomic methods, we anticipate that the combined computational-experimental approach will greatly expand the diversity of known CRISPR-Cas systems, enabling new technologies for biological research and clinical applications.

METHODS {#S1}
=======

Metagenomics and metatranscriptomics {#S2}
------------------------------------

Metagenomic samples from three different sites were analyzed: (1) Acid mine drainage (AMD) samples collected between 2006 and 2010 from the Richmond Mine, Iron Mountain, California^[@R36],[@R37]^ (2) Groundwater and sediment samples collected between 2007 and 2013 from the Rifle Integrated Field Research (IFRC) site, adjacent to the Colorado River near Rifle, Colorado^[@R6],[@R26]^. (3) Groundwater collected in 2009 and 2014 from Crystal Geyser, a cold, CO~2~-driven geyser on the Colorado Plateau in Utah^[@R38]^.

For the AMD data, DNA extraction methods and short read sequencing were reported by Denef and Banfield (2012)^[@R36]^ and Miller *et al*. (2011)^[@R37]^. For the Rifle data, DNA extraction, sequencing, assembly, and genome reconstruction were described by Anantharaman *et al*. (2016)^[@R26]^ and Brown *et al*. (2015)^[@R6]^. For samples from Crystal Geyser, methods follow those described by Probst *et al*. (2016)^[@R38]^ and Emerson *et al*. (2016)^[@R39]^. Rifle metatranscriptomic data was used from the data reported by Brown *et al*. (2015)^[@R6]^.

Briefly, DNA was extracted from samples using the PowerSoil DNA Isolation Kit (MoBio Laboratories Inc., Carlsbad, CA, USA). RNA was extracted from 0.2 μm filters collected from six 2011 Rifle groundwater samples. Following RNA extraction using the Invitrogen TRIzol reagent, DNA removal was done with the Qiagen RNase-Free DNase Set and Qiagen Mini RNeasy kits, and cDNA template library was generated using the Applied Biosystems SOLiD Total RNA-Seq kit. DNA was sequenced on Illumina HiSeq2000 platform, and Metatrancriptomic cDNA on 5500XL SOLiD platform after emulsion clonal bead amplification using the SOLiD EZ Bead system (Life Technologies). For the Crystal Geyser data and reanalysis of the AMD data, sequences were assembled using IDBA-UD^[@R40]^. DNA and RNA (cDNA) read-mapping used to determine sequencing coverage and gene expression, respectively, was performed using Bowtie2^[@R41]^. Open reading frames (ORFs) were predicted on assembled scaffolds using Prodigal^[@R42]^. Scaffolds from the Crystal Geyser dataset were binned on the basis of differential coverage abundance patterns using a combination of ABAWACA^[@R6]^, ABAWACA2 (<https://github.com/CK7>), Maxbin2^[@R43]^, and tetranucleotide frequency using Emergent Self-Organizing Maps (ESOM)^[@R44]^. Genomes were manually curated using % GC content, taxonomic affiliation, and genome completeness. Scaffolding errors were corrected using ra2.py (<https://github.com/christophertbrown>).

CRISPR-Cas computation analyses {#S3}
-------------------------------

The assembled contigs from the various samples were scanned for known Cas proteins using Hidden Markov Model (HMMs) profiles, which were built using the HMMer suite^[@R34]^, based on alignments from Makarova *et al.* (2015)^[@R3]^ and Shmakov *et al.* (2015)^[@R4]^. CRISPR arrays were identified using a local version of the CrisprFinder software^[@R45]^. Loci that contained both Cas1 and a CRISPR array were further analyzed if one of the ten ORFs adjacent to the *cas1* gene encoded for an uncharacterized protein larger than 800 aa, and no known *cas* interference genes were identified on the same contig. These large proteins were further analyzed as potential class 2 Cas effectors. The potential effectors were clustered to protein families based on sequence similarities using MCL^[@R46]^. These protein families were expanded by building HMMs representing each of these families, and using them to search the metagenomic datasets for similar Cas proteins. To compare the identified protein families to known proteins, homologs were searched using BLAST^[@R47]^ against NCBI's non-redundant (nr) and metagenomic (env_nr) protein databases, as well as HMM searches against the UniProt KnowledegeBase^[@R34],[@R48]^. Only proteins with no full-length hits (\> 25% of the protein's length) were considered novel proteins. Distant homology searches of the putative Cas proteins were performed using HHpred from the HH-suite^[@R49]^. High scoring HHpred hits were used to infer domain architecture based on comparison to solved crystal structures^[@R50],[@R51]^, and secondary structure that was predicted by JPred4^[@R52]^. Protein modeling was performed using Phyre2^[@R53]^. The HMM database, including the newly discovered Cas proteins, is available in Supplementary Data 6.

Spacer sequences were determined from the assembled data using CrisprFinder^[@R45]^. CRASS^[@R54]^ was used to locate additional spacers in short DNA reads of the relevant samples. Spacer targets (protospacers) were then identified by BLAST^[@R47]^ searches (using "-task blastn-short") against the relevant metagenomic assemblies for hits with ≤ 1 mismatch to spacers. Hits belonging to contigs that contained an associated repeat were filtered out (to avoid identifying CRISPR arrays as protospacers). Protospacer adjacent motifs (PAMs) were identified by aligning regions flanking the protospacers and visualized using WebLogo^[@R55]^. In cases that one spacer had multiple putative protospacers with different composition of flanking nucleotides, each distinct combination of protospacer and downstream nucleotides was taken into account for the logo calculation. RNA structures were predicted using mFold^[@R56]^. Average nucleotide identity was computed with the pyani Python module (<https://github.com/widdowquinn/pyani>), using the Mummer^[@R57]^ method. CRISPR array diversity was analyzed by manually aligning spacers, repeats and flanking sequences from the assembled data. Manual alignments and contig visualizations were performed with Geneious 9.1.

For the phylogenetic analyses of Cas1 and Cas9 we used proteins of the newly identified systems along with the proteins from Makarova *et al.* (2015)^[@R3]^ and Shmakov *et al.* (2015)^[@R4]^. A non-redundant set was compiled by clustering together proteins with ≥ 90% identity using CD-HIT^[@R58]^. Alignments were produced with MAFFT^[@R59]^, and maximum-likelihood phylogenies were constructed using RAxML^[@R60]^ with PROTGAMMALG as the substitution model and 100 bootstrap samplings. Cas1 tree were rooted using the branch leading to casposons. Trees were visualized using FigTree 1.4.1 (<http://tree.bio.ed.ac.uk/software/figtree/>) and iTOL v3^[@R61]^.

Generation of heterologous plasmids {#S4}
-----------------------------------

Metagenomic contigs were made into minimal CRISPR interference plasmids by removing proteins associated with acquisition for CRISPR-CasX and reducing the size of the CRISPR array for both CRISPR-CasX and CRISPR-CasY. The minimal locus was synthesized as Gblocks (Integrated DNA Technology). Native promoters were used, with the exception of the overexpression of CasY.1 and expression of the crRNA alone or sgRNA for CasX in [figure 3g](#F11){ref-type="fig"} where the J23119 constitutive promoter was used. The minimal CRISPR loci were assembled using Gibson Assembly^[@R62]^ into a plasmid with a p15A origin of replication and chloramphenicol resistance gene. Detailed plasmid maps are available at the links provided in Supplementary Table 2.

PAM depletion assay {#S5}
-------------------

PAM depletion assays were conducted as previously described^[@R63]^ with modification. Plasmid libraries containing randomized PAM sequences were assembled by annealing a DNA oligonucleotide containing a target with a 7 nt randomized PAM region with a primer (Supplementary Table 2) and extended with Klenow Fragment (NEB). The double stranded DNA was digested with EcoRI and NcoI and ligated into a pUC19 backbone. The ligated library was transformed into *E. coli* DH5α and \>10^8^ cells were harvested and the plasmids extracted and purified. 200 ng of the pooled library was transformed into electrocompetent *E. coli* harboring a CRISPR locus or a control plasmid with no locus. The transformed cells were plated on selective media containing carbenicillin (100 mg L^−1^) and chloramphenicol (30 mg L^−1^) for 30 hours at 25°C. Plasmid DNA was extracted and the PAM sequence was amplified with adapters for Illumina sequencing. The 7 nt PAM region was extracted and PAM frequencies calculated for each 7 nt sequence. PAM sequences depleted above the specified threshold were used to generate a sequence logo with WebLogo^[@R55]^.

Plasmid Interference {#S6}
--------------------

Putative targets identified from metagenomic sequence analysis or PAM depletion assays were cloned into a pUC19 plasmid. 10 ng of target plasmid were transformed into electrocompetent *E. coli* (NEB Stable) containing the CRISPR loci plasmid. CasX.1 was used for the plasmid interference assays under control of native promoters or using a strong heterologous promoter (J23119) for sgRNA and crRNA expression. CasY.1 was put under the control of a heterologous promoter (J23119) for these assays. Cells were recovered for 2 hrs at 25°C in Super Optimal Broth (SOB) and an appropriate dilution was plated on selective media. Plates were incubated at 25°C and colony forming units were counted. All plasmid interference experiments were performed in triplicate and electrocompetent cells were prepared independently for each replicate.

Northern Blots {#S7}
--------------

*E. coli* containing the deltaproteobacteria CasX CRISPR locus was grown to OD~600~=1 at 25°C in SOB media. RNA was extracted by warm phenol extraction, separated on 10% denaturing polyacrylamide gel and blotted as previously described by Zhang *et al.* (2013)^[@R64]^.

ARMAN-Cas9 protein expression and purification {#S8}
----------------------------------------------

Expression constructs for Cas9 from ARMAN-1 (AR1) and ARMAN-4 (AR4) were assembled from gBlocks (Integrated DNA Technologies) that were codon-optimized for *E. coli*. The assembled genes were cloned into a pET-based expression vector as an N-terminal His~6~-MBP or His~6~ fusion protein. Expression vectors were transformed into BL21(DE3) *E. coli* cells and grown in LB broth at 37°C. For protein expression, cells were induced during mid-log phase with 0.4 mM IPTG (isopropyl β-D-1-thiogalactopyranoside) and incubated overnight at 16°C. All subsequent steps were conducted at 4°C. Cell pellets were resuspended in lysis buffer (50mM Tris-HCl pH 8, 500 mM NaCl, 1 mM TCEP, 10 mM Imidazole 0.5% Triton X-100) and supplemented with Complete protease inhibitor mixture (Roche) before lysis by sonication. Lysate was clarified by centrifugation at 15000g for 40 min and applied to Superflow Ni-NTA agarose (Qiagen) in batch. The resin was washed extensively with Wash Buffer A (50 mM Tris-HCl pH 8, 500 mM NaCl, 1mM TCEP, 10 mM Imidazole) followed by 5 column volumes of Wash Buffer B (50 mM Tris-HCl pH 8, 1M NaCl, 1 mM TCEP, 10 mM Imidazole). Protein was eluted off of Ni-NTA resin with Elution Buffer (50 mM Tris-HCl pH 8, 500 mM NaCl, 1 mM TCEP, 300 mM Imidazole). The His~6~-MBP tag was removed by TEV protease during overnight dialysis against Wash Buffer A. Cleaved Cas9 was removed from the affinity tag through a second Ni-NTA agarose column. The protein was dialyzed into IEX Buffer A (50 mM Tris-HCl pH 7.5, 300 mM NaCl, 1 mM TCEP, 5% glycerol) before application to a 5 mL Heparin HiTrap column (GE Life Sciences). Cas9 was eluted over a linear NaCl (0.3--1.5 M) gradient. Fractions were pooled and concentrated with a 30 kDa spin concentrator (Thermo Fisher). When applicable, Cas9 was further purified via size-exclusion chromatography on a Superdex 200 pg column (GE Life Sciences) and stored in IEX Buffer A for subsequent cleavage assays. For yeast expression, AR1-Cas9 was cloned into a Gal1/10 His6-MBP TEV Ura *S. cerevisiae* expression vector (Addgene plasmid \# 48305). The vector was transformed into a BY4741 URA3 strain and cultures were grown in CSM media at 30°C. At an OD600 of \~0.6, protein expression was induced with 2% w/v galactose and incubated overnight at 16°C. Protein purification was performed as above.

RNA *in vitro* transcription and oligonucleotide purification {#S9}
-------------------------------------------------------------

*In vitro* transcription reactions were performed as previously described^[@R65]^ using synthetic DNA templates containing a T7 promoter sequence. All *in vitro* transcribed putative guide RNA sequences and target RNA or DNA were purified via denaturing PAGE. Double-stranded target RNA and DNA were hybridized in 20 mM Tris HCl pH 7.5 and 100 mM NaCl by incubation at 95°C for 1 min, followed by slow-cooling to room temperature. Hybrids were purified by native PAGE. RNA and DNA sequences used in this study are listed in Supplementary Table 2.

*In vitro* cleavage assays {#S10}
--------------------------

Purified DNA and RNA oligonucleotides were radiolabeled using T4 polynucleotide kinase (NEB) and \[γ-32P\] ATP (Perkin-Elmer) in 1× PNK buffer for 30 min at 37°C. PNK was heat inactivated at 65°C for 20 min and free ATP was removed from the labeling reactions using illustra Microspin G-25 columns (GE Life Sciences). CrRNA and tracrRNA were mixed in equimolar quantities in 1× refolding buffer (50 mM Tris HCl pH 7.5, 300 mM NaCl, 1 mM TCEP, 5% glycerol) and incubated at 70°C for 5 min and then slow-cooled to room temperature. The reactions were supplemented to 1 mM final metal concentration and subsequently heated at 50°C for 5 min. After slow-cooling to room temperature, refolded guides were placed on ice. Unless noted for buffer or salt concentration, Cas9 was reconstituted with an equimolar amount of guide in 1× cleavage buffer (50 mM Tris HCl pH 7.5, 300 mM NaCl, 1 mM TCEP, 5% glycerol, 5 mM divalent metal) at 37°C for 10 min. Cleavage reactions were conducted in 1× cleavage buffer with a 10× excess of Cas9-guide complex over radiolabeled target at 37°C or the indicated temperature. Reactions were quenched in an equal volume of gel loading buffer supplemented with 50mM EDTA. Cleavage products were resolved on 10% denaturing PAGE and visualized by phosphorimaging.

*In vivo E. coli* interference assays {#S11}
-------------------------------------

*E. coli* transformation assays for ARMAN-1 Cas9 and ARMAN-4 Cas9 were conducted as previously published^[@R66]^. Briefly, *E. coli* transformed with plasmids expressing guide RNA sequences were made electrocompetent. Cells were then transformed with 9 fmol of plasmid encoding wild-type or catalytically inactive Cas9 (dCas9). A dilution series of recovered cells was plated on LB plates with selective antibiotics. Colonies were counted after 16 hr at 37°C.

Data Availability {#S12}
-----------------

All the sequences reported in this study for the first time have been deposited in NCBI database under BioProject PRJNA349044. The NCBI Nucleotide database accession and coordinates of each locus are specified in [Extended Data Table 1](#T1){ref-type="table"}. The BioSample and Sequence Reads Archive (SRA) accessions for the ARMAN-1 spacers and protospacers are detailed in Supplementary Table 1. The HMMs used in this study are provided in Supplementary Data 6.

Extended Data {#S13}
=============

![Multiple sequences alignment of newly described Cas9 proteins\
Alignment of Cas9 proteins from ARMAN-1 and ARMAN-4, as well as two closely related Cas9 proteins from uncultivated bacteria, to the *Actinomyces naeslundii* Cas9, whose structure has been solved^[@R67]^.](nihms837428f1){#F1}

![Within-population variability of ARMAN-1 CRISPR arrays\
Variability of reconstructed CRISPR arrays, including the most well represented (and thus assembled) sequences ([Fig. 2](#F10){ref-type="fig"}) and array segments representing locus variants that were reconstructed from the short DNA reads. Variability is due to spacers that were present in only a subset of archaeal cells in the population, as well as spacers whose context differed due to spacer loss (indicated by black lines). White boxes indicate repeats and colored arrows indicate CRISPR spacers (spacers with different colors have different sequences, except for unique spacers that are black). In CRISPR systems, spacers are typically added unidirectionally, so the high variety of spacers on the left side is attributed to recent acquisition.](nihms837428f2){#F2}

![Novelty of the reported CRISPR-Cas systems\
**a**, Simplified phylogenetic tree of the universal Cas1 protein. CRISPR types of known systems are noted on the wedges and branches; the newly described systems are in bold. Detailed Cas1 phylogeny is provided in Supplementary Data 4. **b**, Proposed evolutionary scenario that gave rise to the archaeal type II system as a result of a recombination between type II-B and type II-C loci. c, Similarity of CasX and CasY to known proteins based on the following searches: (1) Blast search against the non-redundant (NR) protein database of NCBI, (2) HMM search against an HMM database of known Cas proteins and (3) distant homology search using HHpred^[@R49]^ (E, e-value).](nihms837428f3){#F3}

![Evolutionary tree of Cas9 homologs\
Maximum-likelihood phylogenic tree of Cas9 proteins, showing the previously described systems colored based on their type: II-A in blue, II-B in green and II-C in purple. The archaeal Cas9 (in red), cluster with type II-C CRISPR-Cas systems, together with two newly described bacterial Cas9 from uncultivated bacteria. Detailed tree is provided in Supplementary Data 5.](nihms837428f4){#F4}

![ARMAN-1 spacers map to genomes of archaeal community members\
**a**, Protospacers from ARMAN-1 map to the genome of ARMAN-2, a nanoarchaeon from the same environment. Six protospacers (red arrowheads) map uniquely to a portion of the genome flanked by two long-terminal repeats (LTRs), and two additional protospacers match perfectly within the LTRs (blue and green arrowheads). This region is likely a transposon, suggesting the CRISPR-Cas system of ARMAN-1 plays a role in suppressing mobilization of this element. **b**, Protospacers also map to a *Thermoplasmatales* archaeon (I-plasma), another member of the Richmond Mine ecosystem that is found in the same samples as ARMAN organisms. The protospacers cluster within a region of the genome encoding short, hypothetical proteins, suggesting this might also represent a mobile element. NCBI accessions are provided in parenthesis.](nihms837428f5){#F5}

![Archaeal Cas9 from ARMAN-4 with a degenerate CRISPR array is found on numerous contigs\
Cas9 from ARMAN-4 is highlighted in dark red on 16 nearly identical contigs from different samples. Proteins with putative domains or functions are labeled whereas hypothetical proteins are unlabeled. Fifteen of the contigs contain two degenerate direct repeats (36 nt long with one mismatch) and a single conserved spacer of 36 nt. The remaining contig contains only one direct repeat. Unlike ARMAN-1, no additional Cas proteins are found adjacent to Cas9 in ARMAN-4.](nihms837428f6){#F6}

![Predicted structures of guide RNA and purification schema for *in vitro* biochemistry studies\
**a**, The CRISPR repeat and tracrRNA anti-repeat are depicted in black whereas the spacer-derived sequence is shown as a series of green N's. No clear termination signal can be predicted from the locus, so three different tracrRNA lengths were tested based on their secondary structure -- 69, 104, and 179 nt in red, blue, and pink, respectively. **b**, Engineered single-guide RNA corresponding to dual-guide in **(a). c**, Dual-guide for ARMAN-4 Cas9 with two different hairpins on 3′ end of tracrRNA (75 and 122 nt). **d**, Engineered single-guide RNA corresponding to dual-guide in **(c)**. **e**, Conditions tested in *E. coli in vivo* targeting assay. **f**, ARMAN-1 (AR1) and ARMAN-4 (AR4) Cas9 were expressed and purified under a variety of conditions as outlined in the Methods section. Proteins outlined in blue boxes were tested for cleavage activity *in vitro*. **g**, Fractions of AR1-Cas9 and AR4-Cas9 purifications were separated on a 10% SDS-PAGE gel.](nihms837428f7){#F7}

![Programmed DNA interference by CasX\
**a**, Plasmid interference assays for CasX.1 (Deltaproteobacteria) and CasX.2 (Planctomycetes), continued from [Figure 3c](#F11){ref-type="fig"} (sX1, CasX spacer 1; sX2, CasX spacer 2; NT, non-target). Experiments were conducted in triplicate and mean ± s.d. is shown. **b**, Serial dilution of *E. coli* expressing a CasX locus and transformed with the specified target, continued from [Figure 3b](#F11){ref-type="fig"}. **c**, PAM depletion assays for the Deltaproteobacteria CasX and **d**, Planctomycetes CasX expressed in *E. coli.* PAM sequences depleted greater than the indicated PAM depletion value threshold (PDVT) compared to a control library were used to generate the sequence logo. **e**, Diagram depicting the location of Northern blot probes for CasX.1. **f**, Northern blots for CasX.1 tracrRNA in total RNA extracted from *E. coli* expressing the CasX.1 locus. The sequences of the probes used are provided in Supplementary Table 2.](nihms837428f8){#F8}

###### CRISPR-Cas loci identified in this study

Details regarding the organisms and genomic location in which the CRISPR-Cas system were identified, as well as information on the number and average length of reconstructed spacers, and repeats length (NA, not available). ARMAN-1 spacers were reconstructed from 16 samples, see details in Supplementary Table 1.

  Taxonomic group              Cas effector   NCBI Accession   Coordinates    Repeat length   \# spacers   Spacers avg. length
  ---------------------------- -------------- ---------------- -------------- --------------- ------------ ---------------------
  ARMAN-1                      Cas9           MOEG01000017     1827..7130     36              271          34.5
  ARMAN-4                      Cas9           KY040241         11779..14900   36              1            36
  Deltaproteobacteria          CasX           MGPG01000094     4319..9866     37              5            33.6
  Planctomycetes               CasX           MHYZ01000150     1..5586        37              7            32.3
  Candidatus Katanobacteria    CasY.1         MOEH01000029     459..5716      26              14           17.1
  Candidatus Vogelbacteria     CasY.2         MOEJ01000028     7322..13087    26              18           17.3
  Candidatus Vogelbacteria     CasY.3         MOEK01000006     1..4657        26              12           17.3
  Candidatus Parcubacteria     CasY.4         KY040242         1..5193        25              13           18.4
  Candidatus Komeilibacteria   CasY.5         MOEI01000022     2802..7242     36              8            26
  Candidatus Kerfeldbacteria   CasY.6         MHKD01000036     11503..15366   NA              NA           NA

###### 

*In vitro* cleavage conditions assayed for Cas9 from ARMAN-1 and ARMAN-4.

  -----------------------------------------------------------------------------------------------------
  Protein Purification   Buffer           Salt (mM)   Metal     Guide       Target        Temperature
  ---------------------- ---------------- ----------- --------- ----------- ------------- -------------
  AR1-Cas9 \#1           Tris pH 7.5      300         Mg^2+^\   crRNA\      dsDNA\        37
                                                      Mn^2+^\   cr:69\      ssDNA\        
                                                      Zn^2+^    cr:104\     DNA Bubble\   
                                                                cr:179      ssRNA\        
                                                                            dsDNA         

  AR1-Cas9 \#1           Tris pH 7.5      100--500    Mg^2+^    cr:69\      dsDNA         37
                                                                cr:104\                   
                                                                cr:179                    

  AR1-Cas9 \#1           Tris pH 7.5      300         Mg^2+^\   cr:69\      dsDNA         30--48
                                                      Mn^2+^\   cr:104\                   
                                                      Zn^2+^    cr:179                    

  AR1-Cas9 \#1           MOPS: pH 6\      300         Mg^2+^    cr:69\      dsDNA         37
                         pH 6.5\                                cr:104\                   
                         pH 7.0\                                cr:179                    
                         pH 7.5                                                           

  AR1-Cas9 \#1           Citrate: pH 5\   300         Mg^2+^    cr:69\      dsDNA         37
                         pH 5.5\                                cr:104\                   
                         pH 6                                   cr:179                    

  AR1-Cas9 \#1           Tris pH 7.5      300         Mg^2+^\   cr:69\      plasmid       37--50
                                                      Mn^2+^\   cr:104\                   
                                                      Zn^2+^    cr:179                    

  AR1-Cas9 \#2           Tris pH 7.5      300         Mg^2+^\   cr:69\      dsDNA         37
                                                      Mn^2+^\   cr:104\                   
                                                      Zn^2+^    cr:179                    

  AR1-Cas9 \#3           Tris pH 7.5      300         Mg^2+^\   cr:69\      dsDNA         37
                                                      Mn^2+^\   cr:104\                   
                                                      Zn^2+^    cr:179                    

  AR1-Cas9 \#4           Tris pH 7.5      300         Mg^2+^\   cr:69\      dsDNA         37
                                                      Mn^2+^\   cr:104\                   
                                                      Zn^2+^    cr:179                    

  AR1-Cas9 \#5           Tris pH 7.5      300         Mg^2+^\   cr:69\      dsDNA         37
                                                      Mn^2+^\   cr:104\                   
                                                      Zn^2+^    cr:179                    

  AR1-Cas9 \#6           Tris pH 7.5      300         Mg^2+^\   cr:69\      ssDNA\        37
                                                      Mn^2+^\   cr:104\     dsDNA         
                                                      Zn^2+^    cr:179                    

  AR4-Cas9 \#1           Tris ph7.5       300         Mg^2+^\   sgRNA-122   dsDNA         37
                                                      Mn^2+^\                             
                                                      Zn^2+^                              

  AR4-Cas9 \#2           Tris ph7.5       300         Mg^2+^\   sgRNA-122   dsDNA         37
                                                      Mn^2+^\                             
                                                      Zn^2+^                              

  AR4-Cas9 \#3           Tris ph7.5       300         Mg^2+^\   sgRNA-122   dsDNA         37
                                                      Mn^2+^\                             
                                                      Zn^2+^                              

  AR4-Cas9 \#4           Tris ph7.5       300         Mg^2+^\   sgRNA-122   dsDNA         37
                                                      Mn^2+^\                             
                                                      Zn^2+^                              
  -----------------------------------------------------------------------------------------------------
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![CRISPR-Cas systems identified in uncultivated organisms\
**a**, Ratio of lineages with and without isolated representatives in Bacteria and Archaea, based on 31 major lineages described by Hug *et al*. (2016)^[@R29]^. The results highlight the massive scale of as-yet little investigated biology in these domains. Archaeal Cas9 and the novel CRISPR-CasY were found exclusively in lineages with no isolated representatives. **b**, Locus organization of the discovered CRISPR-Cas systems.](nihms837428f9){#F9}

![ARMAN-1 CRISPR array diversity and identification of the ARMAN-1 Cas9 PAM sequence\
**a**, CRISPR arrays reconstructed from AMD samples. White boxes indicate repeats and colored diamonds indicate spacers (identical spacers are similarly colored; unique spacers are in black). The conserved region of the array is highlighted. The diversity of recently acquired spacers (on the left) indicates the system is active. Analysis of within-population CRISPR variability is presented in [Extended Data Fig. 2](#F2){ref-type="fig"}. **b**, A single circular, putatively viral, contig contains 56 protospacers (red vertical bars) from the ARMAN-1 CRISPR arrays. **c**, Sequence analysis of 240 protospacers (Supplementary Table 1) revealed a conserved 'NGG' PAM downstream to the protospacers.](nihms837428f10){#F10}

![CRISPR-CasX is a dual-guided system that mediates programmable DNA interference in *E. coli*\
**a**, Diagram of CasX plasmid interference assays. **b**, Serial dilution of *E. coli* expressing the Planctomycetes CasX locus with spacer 1 (sX1) and transformed with the specified target (sX1, CasX protospacer 1; sX2, CasX protospacer 2; NT, non-target). **c**, Plasmid interference by Deltaproteobacteria CasX, using the same spacers and targets as in (**b**). **d**, PAM depletion assays for the Planctomycetes CasX locus expressed in *E. coli*. Sequence logo was generated from PAM sequences depleted \> 30-fold compared to a control library (see also [Extended Data Fig. 8](#F8){ref-type="fig"}). **e**, Diagram of CasX DNA interference. **f**, Mapping of environmental RNA sequences to the CasX CRISPR locus (red arrow, putative tracrRNA; white boxes, repeats; green diamonds, spacers); Inset: detailed view of mapping to first repeat and spacer. **g**, Plasmid interference assays with the putative tracrRNA knocked out of the CasX locus and CasX coexpressed with a crRNA alone, a truncated sgRNA or a full length sgRNA (T, target; NT, non-target). Experiments presented in (**c**) and (**g**) were conducted in triplicate and mean ± s.d. is shown.](nihms837428f11){#F11}

![Expression of a CasY locus in *E. coli* is sufficient for DNA interference\
**a**, Diagrams of CasY loci and neighboring proteins. **b**, Sequence logo of the 658 5′ PAM sequences depleted greater than 3-fold by CasY relative to a control library. **c**, Plasmid interference by *E. coli* expressing CasY.1 and CRISPR array expressed with a heterologous promoter and transformed with targets containing the indicated PAM. Experiments were conducted in triplicate and mean ± s.d. is shown.](nihms837428f12){#F12}
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